Activation of the AXL receptor is reported to aberrantly phosphorylate SMAD3 to induce EMT in hepatocellular carcinoma (HCC) progression in collaboration with TGF‐β (Reichl et al., 2015). This evidence concerns the gene TGFB1 and hepatocellular carcinoma.